Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
FI: 3,231
Type: Article
Collaboration
Year: 2021
Writers
Abrisqueta, P; Loscertales, J; Terol, M. J.; Payer, AR; Ortiz, M.; Perez, I; Cuellar-Garcia, C; de la Mata, MF; Rodriguez, A; Lario, A; Delgado, J.; Godoy, A; Perez, JMA; Berruezo, MJ; Oliveira, A; Hernandez-Rivas, JA; Bad, MDG; Medina, A; Martin, P. G.; Osorio,
Magazine
Title: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Quartile
- Q3